<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407041</url>
  </required_header>
  <id_info>
    <org_study_id>GT-030</org_study_id>
    <nct_id>NCT02407041</nct_id>
  </id_info>
  <brief_title>An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis</brief_title>
  <official_title>A Single-Center, Open-Label Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Patients With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galectin Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galectin Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to&#xD;
      severe plaque psoriasis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective is to establish the safety and efficacy of GR-MD-02 in patients with&#xD;
      moderate to severe plaque psoriasis.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      The objective is to evaluate the number of patients with moderate to severe plaque psoriasis&#xD;
      who have 75% improvement in Psoriasis Activity Severity Index (PASI-75) following 12 weeks of&#xD;
      therapy with GR-MD-02&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To determine the PASI-50 and PASI-100 scores in patients with moderate to severe plaque&#xD;
           psoriasis following the first 12 weeks of therapy with GR-MD-02&#xD;
&#xD;
        -  To determine the PASI-50, PASI-75, and PASI-100 scores in patients with moderate to&#xD;
           severe plaque psoriasis following an additional 12 weeks of therapy (total 24 weeks)&#xD;
           with GR-MD-02&#xD;
&#xD;
        -  To determine the durability of response to therapy in responders over a one year period&#xD;
           following the end of therapy&#xD;
&#xD;
        -  To determine whether there is any change in disease status of patients who also have&#xD;
           psoriatic arthritis&#xD;
&#xD;
        -  To determine the incidence of adverse events and vital sign and laboratory abnormalities&#xD;
           during study treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With PASI-75, or a 75% Improvement From Baseline in PASI Score</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint will be the number of participants with PASI-75, or a 75% improvement from baseline (day 1, prior to first infusion) in PASI score as assessed at the 30 day follow up visit.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>GR-MD-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GR-MD-02</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>GR-MD-02</arm_group_label>
    <other_name>galactoarabino-rhamnogalacturonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each subject must meet all of the following criteria to be enrolled in this study:&#xD;
&#xD;
          1. Is capable of understanding the written informed consent, provides signed and&#xD;
             witnessed written informed consent, and agrees to comply with protocol requirements.&#xD;
&#xD;
          2. Is between the ages of 18 and 75 years.&#xD;
&#xD;
          3. Has biopsy proven psoriasis and active moderate to severe plaque psoriasis with a PASI&#xD;
             of â‰¥ 12 and at least 10% of involved body surface area.&#xD;
&#xD;
          4. The patient is not pregnant and must have a negative pregnancy test prior to start of&#xD;
             the study. Post-menopausal women must have been amenorrheic for at least 12 months to&#xD;
             be considered of non-child-bearing potential.&#xD;
&#xD;
          5. Sexually active men or women of childbearing potential must agree to use effective&#xD;
             means of contraception throughout their participation in this study and for 90 days&#xD;
             after discontinuation of study medication.&#xD;
&#xD;
          6. Lactating females must agree to discontinue nursing before the start of study&#xD;
             treatment and refrain from nursing until 90 days after discontinuation of study&#xD;
             medication.&#xD;
&#xD;
          7. Male subjects must refrain from sperm donation throughout the study period and for a&#xD;
             period of 90 days following the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. Any medical illness that is not stable on therapy&#xD;
&#xD;
          2. Use of any biologic medication for psoriasis within 6 months&#xD;
&#xD;
          3. Use of or non-biological systemic therapy to include: methotrexate, oral retinoids,&#xD;
             phototherapy/PUVA, cyclosporine, or any other cytotoxic or immunosuppressive&#xD;
             medication within 4 weeks of start of study&#xD;
&#xD;
          4. Topical treatment that is likely to impact signs and symptoms of psoriasis, in the&#xD;
             opinion of the Principal Investigator, within 2 weeks of the start of the study&#xD;
&#xD;
          5. Prior exposure to GR-MD-02&#xD;
&#xD;
          6. Known positivity for Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          7. Any patient who had major surgery within 8 weeks of Day 1, significant traumatic&#xD;
             injury, or anticipation of need for major surgical procedure during the study.&#xD;
&#xD;
          8. Has a history of alcohol/drug abuse.&#xD;
&#xD;
          9. Any patient who has clinically significant and uncontrolled cardiovascular disease&#xD;
             (e.g., uncontrolled hypertension, myocardial infarction, unstable angina), New York&#xD;
             Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac&#xD;
             arrhythmia requiring medication, or Grade II or greater peripheral vascular disease&#xD;
             within 12 months prior to Day 1.&#xD;
&#xD;
         10. Any patient with concurrent infection including diagnoses of fever of unknown origin&#xD;
             (FUO) (subjects must be afebrile at the start of therapy).&#xD;
&#xD;
         11. History of malignant disease with a recurrence of that disease within 5 years of&#xD;
             follow-up except for those that have been curatively treated including basal or&#xD;
             squamous cell carcinoma of the skin and in situ carcinoma of the cervix&#xD;
&#xD;
         12. Participation in an investigational new drug (IND) trial in the 30 days before&#xD;
             randomization.&#xD;
&#xD;
         13. Clinically significant medical or psychiatric condition considered a high risk for&#xD;
             participation in an investigational study.&#xD;
&#xD;
         14. Has donated or lost a significant volume (&gt;450 mL) of blood or plasma within 30 days&#xD;
             of the study.&#xD;
&#xD;
         15. Failure to give informed consent&#xD;
&#xD;
         16. Subjects with known allergies to the study drug or any of its excipients.&#xD;
&#xD;
         17. Is an employee or family member of the investigator or study site personnel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brooke Army Medical Ctr.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>September 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 7, 2020</results_first_posted>
  <disposition_first_submitted>July 31, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 31, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 2, 2018</disposition_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02407041/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GR-MD-02</title>
          <description>active arm&#xD;
GR-MD-02: IV infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GR-MD-02 8 mg/kg</title>
          <description>active arm, 8 mg/kg&#xD;
GR-MD-02: IV infusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With PASI-75, or a 75% Improvement From Baseline in PASI Score</title>
        <description>The primary endpoint will be the number of participants with PASI-75, or a 75% improvement from baseline (day 1, prior to first infusion) in PASI score as assessed at the 30 day follow up visit.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GR-MD-02 8 mg/kg</title>
            <description>active arm, 8 mg/kg&#xD;
GR-MD-02: IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With PASI-75, or a 75% Improvement From Baseline in PASI Score</title>
          <description>The primary endpoint will be the number of participants with PASI-75, or a 75% improvement from baseline (day 1, prior to first infusion) in PASI score as assessed at the 30 day follow up visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GR-MD-02 8 mg/kg</title>
          <description>active arm, 8 mg/kg&#xD;
GR-MD-02: IV infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President of Regulatory Affairs</name_or_title>
      <organization>Galectin Therapeutics</organization>
      <phone>678-620-3186</phone>
      <email>horton@galectintherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

